| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3336062 | Transfusion and Apheresis Science | 2008 | 8 Pages |
Abstract
Children and adolescents comprise a significant proportion of the hemophilia population, including those patients who have developed inhibitors to factor VIII or FIX. We examine the use of rFVIIa for the treatment of bleeding episodes and the prevention of bleeding in children and adolescents with hemophilia A and B with inhibitors, focusing on registry data and recent clinical trial results. Based on this review of the literature, we conclude that recombinant FVIIa is safe and effective for use in controlling bleeding in these patient populations.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Brahm Goldstein, Brian Geldziler, Jens Bjerre, Stephanie Seremetis,